adalimumab-atto (Amjevita) vs golimumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab-atto (Amjevita)

Marketed by Amgen

Approved in Ulcerative Colitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Reliable signal

NCT01863771 · Phase 3 · completed

Design meets the 'strong' bar: randomized, double-blind (participant and investigator masked), placebo-controlled, phase 3, with a hard clinical endpoint (Mayo score-based clinical response); the primary comparison was clearly met in the favorable direction (18/32 vs 6/31, non-overlapping 95% CIs).

Reported efficacy

Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) (met)

Result source: NCT01863771

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-atto (Amjevita)golimumab
Clinical remission (induction)—Not reported17.9% vs 6.4%+11.5 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 17.8% vs 6.4% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · secondary NCT00487539
Clinical remission (maintenance)—Not reported—Trial running · NCT03596645
Clinical response (induction)—Not reported54.9% vs 30.3%+24.6 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 51% vs 30.3% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · primary NCT00487539
Endoscopic improvement (induction)—Not reported—Trial running · NCT03596645
Corticosteroid-free remission (maintenance)—Not reported23.2% vs 18.4%+4.8 vs placebo100 mg · wk 54 · n 82NCT00488631
1 other result
  • 28.2% vs 18.4% 50 mg · wk 54 · n 78 · Phase 3 · secondary NCT00488631

Clinical remission (induction)

adalimumab-atto (Amjevita)
—Not reported
golimumab
17.9% vs 6.4%+11.5 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 17.8% vs 6.4% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · secondary NCT00487539

Clinical remission (maintenance)

adalimumab-atto (Amjevita)
—Not reported
golimumab
—Trial running · NCT03596645

Clinical response (induction)

adalimumab-atto (Amjevita)
—Not reported
golimumab
54.9% vs 30.3%+24.6 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 51% vs 30.3% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · primary NCT00487539

Endoscopic improvement (induction)

adalimumab-atto (Amjevita)
—Not reported
golimumab
—Trial running · NCT03596645

Corticosteroid-free remission (maintenance)

adalimumab-atto (Amjevita)
—Not reported
golimumab
23.2% vs 18.4%+4.8 vs placebo100 mg · wk 54 · n 82NCT00488631
1 other result
  • 28.2% vs 18.4% 50 mg · wk 54 · n 78 · Phase 3 · secondary NCT00488631
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-atto (Amjevita): no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-atto (Amjevita): 0 of 4 rows · golimumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricgolimumab
Dropout rate
—100 mga
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
—100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.6%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—200 mg
NCT00488631 · Phase 3
29.2%100 mg
NCT00488631 · Phase 3 · combination
—100 mg - 200 mg
NCT00488631 · Phase 3
53.3%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg - 200 mg
NCT00488631 · Phase 3
—100 mg
NCT00488631 · Phase 3
44.8%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg
NCT00488631 · Phase 3
27.9%50 mg
NCT00488631 · Phase 3 · combination
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
1.2%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
0.9%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
4.2%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
7.1%Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
4.3%Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
23.7%
NCT02318667 · Phase 4 · registry result, not featured evidence
17.1%
NCT02092285 · Phase 4 · registry result, not featured evidence
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
6.9%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
—100 mga
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
—100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
6.3%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—200 mg
NCT00488631 · Phase 3
7.8%100 mg
NCT00488631 · Phase 3 · combination
—100 mg - 200 mg
NCT00488631 · Phase 3
12.3%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg - 200 mg
NCT00488631 · Phase 3
—100 mg
NCT00488631 · Phase 3
13%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg
NCT00488631 · Phase 3
7.8%50 mg
NCT00488631 · Phase 3 · combination
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
0.3%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
0.3%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
2.8%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
—Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
—Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
2.6%
NCT02318667 · Phase 4 · registry result, not featured evidence
3.4%
NCT02092285 · Phase 4 · registry result, not featured evidence
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
0%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
3.1%100 mga
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
10%100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
3.5%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.3%200 mg
NCT00488631 · Phase 3
14.3%100 mg
NCT00488631 · Phase 3 · combination
7.1%100 mg - 200 mg
NCT00488631 · Phase 3
15.6%100 mg
NCT00488631 · Phase 3 · monotherapy
0%100 mg - 200 mg
NCT00488631 · Phase 3
19.4%100 mg
NCT00488631 · Phase 3
14.8%100 mg
NCT00488631 · Phase 3 · monotherapy
25%100 mg
NCT00488631 · Phase 3
8.4%50 mg
NCT00488631 · Phase 3 · combination
24%50 mg - 100 mg
NCT00488631 · Phase 3
5.3%50 mg - 100 mg
NCT00488631 · Phase 3
11.8%50 mg
NCT00488631 · Phase 3
0%50 mg
NCT00488631 · Phase 3
4.5%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
3%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
4.2%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
9.5%Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
0%Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
10.5%
NCT02318667 · Phase 4 · registry result, not featured evidence
23.9%
NCT02092285 · Phase 4 · registry result, not featured evidence
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
4.5%Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
0%Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
100 mga
nasopharyngitis 53.1% (placebo 22.6%)
injection site erythema 15.6% (placebo 0%)
influenza 12.5% (placebo 3.2%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 26 more results
100 mg
nasopharyngitis 23.3% (placebo 22.6%)
colitis ulcerative 6.7% (placebo 6.5%)
upper respiratory tract inflammation 6.7% (placebo 0%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 11.8% (placebo 22.6%)
colitis ulcerative 4.9% (placebo 6.5%)
injection site erythema 3.5% (placebo 0%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
200 mg
colitis ulcerative 28.6% (placebo 18.6%)
gastroenteritis viral 28.6% (placebo 0%)
nasopharyngitis 28.6% (placebo 6.4%)
NCT00488631 · Phase 3
100 mg
nasopharyngitis 14.9% (placebo 6.4%)
colitis ulcerative 11.7% (placebo 18.6%)
headache 7.8% (placebo 9%)
NCT00488631 · Phase 3 · combination
100 mg - 200 mg
nasopharyngitis 21.4% (placebo 6.4%)
headache 14.3% (placebo 9%)
viral upper respiratory tract infection 14.3% (placebo 0%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 12.1% (placebo 18.6%)
nasopharyngitis 8.1% (placebo 6.4%)
arthralgia 7.2% (placebo 7.1%)
NCT00488631 · Phase 3 · monotherapy
100 mg - 200 mg
colitis ulcerative 30% (placebo 18.6%)
diarrhoea 20% (placebo 4.5%)
gastroenteritis 20% (placebo 1.9%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 23.7% (placebo 18.6%)
nasopharyngitis 16.4% (placebo 6.4%)
sinusitis 9% (placebo 1.9%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 10.9% (placebo 18.6%)
headache 9.6% (placebo 9%)
nasopharyngitis 7.4% (placebo 6.4%)
NCT00488631 · Phase 3 · monotherapy
100 mg
colitis ulcerative 25% (placebo 18.6%)
nasopharyngitis 14.3% (placebo 6.4%)
arthralgia 10.7% (placebo 7.1%)
NCT00488631 · Phase 3
50 mg
colitis ulcerative 16.2% (placebo 18.6%)
nasopharyngitis 9.1% (placebo 6.4%)
headache 8.4% (placebo 9%)
NCT00488631 · Phase 3 · combination
50 mg - 100 mg
nasopharyngitis 16% (placebo 6.4%)
pyrexia 16% (placebo 4.5%)
upper respiratory tract infection 12% (placebo 2.6%)
NCT00488631 · Phase 3
50 mg - 100 mg
colitis ulcerative 10.5% (placebo 18.6%)
dyspepsia 10.5% (placebo 1.3%)
upper respiratory tract infection 10.5% (placebo 2.6%)
NCT00488631 · Phase 3
50 mg
colitis ulcerative 18.3% (placebo 18.6%)
nasopharyngitis 10.8% (placebo 6.4%)
arthralgia 9.7% (placebo 7.1%)
NCT00488631 · Phase 3
50 mg
abdominal pain 100% (placebo 2.6%)
abdominal pain upper 100% (placebo 0.6%)
bite 100% (placebo 0%)
NCT00488631 · Phase 3
400 mg -> 200 mg
headache 4.5% (placebo 5.2%)
nausea 3.6% (placebo 1.8%)
pyrexia 3% (placebo 2.1%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
200 mg -> 100 mg
nasopharyngitis 3.9% (placebo 3.6%)
headache 3.3% (placebo 5.2%)
anaemia 2.4% (placebo 1.8%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
100 mg -> 50 mg
headache 7% (placebo 5.2%)
injection site erythema 4.2% (placebo 0%)
anaemia 2.8% (placebo 1.8%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
colitis ulcerative 10.5%
NCT02318667 · Phase 4 · registry result, not featured evidence
colitis ulcerative 13.7%
nasopharyngitis 9.8%
colitis 7.3%
NCT02092285 · Phase 4 · registry result, not featured evidence
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 11.1%
anaemia 6.9%
upper respiratory tract infection 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 7.5%
anaemia 3%
headache 3%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 5.2%
anaemia 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

golimumab

Clinical Response 54.9% (n=257) vs 30.3% (n=251) placebo @ 6wk400 mg -> 200 mg
responder rate · % of participants
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 141 Participants as posted
show 4 more results
51% (n=253) vs 30.3% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 129 Participants as posted
49.7% (n=151) vs 31.2% (n=154) placebo @ 54wk*100 mg
NCT00488631 · Phase 3 · combination · converted to % from 75 Participants as posted
47% (n=151) vs 31.2% (n=154) placebo @ 54wk*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 71 Participants as posted
56.3% (n=32) vs 19.4% (n=31) placebo @ 54wk*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 18 participants as posted
Clinical Remission 17.9% (n=257) vs 6.4% (n=251) placebo @ 6wk400 mg -> 200 mg
responder rate · % of participants
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 46 Participants as posted
show 2 more results
17.8% (n=253) vs 6.4% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 45 Participants as posted
50% (n=32) vs 6.5% (n=31) placebo*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 16 participants as posted
Mucosal Healing 42.4% (n=151) vs 26.6% (n=154) placebo100 mg
event count · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 64 Participants as posted
show 2 more results
41.7% (n=151) vs 26.6% (n=154) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 63 Participants as posted
59.4% (n=32) vs 16.1% (n=31) placebo*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 19 participants as posted
Sustained Clinical Remission 27.8% (n=151) vs 15.6% (n=154) placebo100 mg
responder rate · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 42 Participants as posted
show 3 more results
38.9% (n=54) vs 24.1% (n=54) placebo*100 mg
NCT00488631 · Phase 3 · combination · converted to % from 21 Participants as posted
23.2% (n=151) vs 15.6% (n=154) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 35 Participants as posted
36.5% (n=52) vs 24.1% (n=54) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 19 Participants as posted
Corticosteroid-free Clinical Remission 23.2% (n=82) vs 18.4% (n=87) placebo @ 54wk100 mg
responder rate · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 19 Participants as posted
show 1 more result
28.2% (n=78) vs 18.4% (n=87) placebo @ 54wk*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 22 Participants as posted
Endoscopic Improvement 45.1% (n=257) vs 28.7% (n=251) placebo @ 6wk400 mg -> 200 mg
event count · % of participants
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 116 Participants as posted
show 1 more result
42.3% (n=253) vs 28.7% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 107 Participants as posted
IBDQ 26.9 vs 14.8 placebo score @ 6wk400 mg -> 200 mg
absolute change · score
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
show 1 more result
27 vs 14.8 placebo score @ 6wk200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
Partial Mayo 24.9% (n=205) @ 54wk
responder rate · % of participants
No placebo or comparator arm
NCT02092285 · Phase 4 · registry result, not featured evidence
Clinical Response 61.1% (n=72) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
show 1 more result
83.1% (n=71) @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
Clinical Remission 22.2% (n=72) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
show 1 more result
36.6% (n=71) @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-atto (Amjevita)

Marketed by Amgen

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01970475 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).

Reported efficacy

Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)

Result source: NCT01970475

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Partial signal

NCT00264537 · Phase 3 · completed

This trial was well designed -- randomized, fully blinded, and placebo-controlled with over 600 patients -- but its two main outcomes told different stories: the joint-damage (structural) outcome clearly favored golimumab plus methotrexate, while the joint-response (ACR50) outcome for the combined golimumab groups narrowly missed statistical significance against placebo, with only one of the individual dose comparisons reaching significance on its own. A well-designed trial with a split result on its co-primary outcomes does not qualify as strong evidence of benefit.

Reported efficacy

ACR20 response at week 14; change from baseline in HAQ score at week 24: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. (met)

Result source: NCT00264550

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-atto (Amjevita)golimumab
ACR2074.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
44.4% vs 33.1%+11.3 vs placebo100 mg + placebo · wk 14 · n 133NCT00264550
25 other results
  • 36.5% vs 18% 100 mg · wk 14 · n 148 · Phase 3 · primary NCT00299546
  • 40.9% vs 15.9% 50 mg · wk 14 · n 132 · Phase 3 · primary NCT01248780
  • 34.7% vs 18% 50 mg · wk 14 · n 147 · Phase 3 · primary NCT00299546
  • 58.5% vs 24.9% 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · primary NCT00973479
  • 56.2% vs 33.1% 100 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 55.1% vs 33.1% 50 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 51.6% vs 49.4% 100 mg + placebo · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 35.3% vs 27.8% 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 42.6% vs 16% 100 mg · wk 24 · n 148 · Phase 3 · secondary NCT00299546
  • 42.4% vs 15.9% 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 31.3% vs 16% 50 mg · wk 24 · n 147 · Phase 3 · secondary NCT00299546
  • 48.1% vs 27.9% 4 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 39.8% vs 27.9% 2 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 61.6% vs 49.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% wk 24 · n 318 · Phase 3 · secondary NCT00264537
  • 59.6% vs 27.8% 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 59.6% vs 27.8% 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 51.6% vs 27.9% 4 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 55% vs 27.9% 2 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 55.9% vs 37.1% 100 mg every 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 79.4% vs 37.1% 100 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 60% vs 37.1% 50 mg every 4 weeks · wk 16 · n 35 · Phase 2 · primary NCT00207714
  • 50% vs 37.1% 50 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 62% vs 65.6% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896
ACR5049.2% vs 52%vs Adalimumabwk 24 · n 244NCT0197047532.7% vs 29.4%+3.3 vs placebo100 mg + placebo · wk 24 · n 159NCT00264537
19 other results
  • 19.4% vs 13.2% 4 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 12.5% vs 13.2% 2 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 36.5% vs 29.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 40.3% vs 29.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 21.1% vs 13.2% 4 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 21.7% vs 13.2% 2 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 38.4% vs 29.4% wk 24 · n 318 · Phase 3 · primary NCT00264537
  • 18.2% vs 6.7% 100 mg · wk 14 · n 148 · Phase 3 · secondary NCT00299546
  • 15% vs 6.7% 50 mg · wk 14 · n 147 · Phase 3 · secondary NCT00299546
  • 34.9% vs 13.2% 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 28.9% vs 35.8% 100 mg + placebo · wk 24 · n 90 · Phase 3 · secondary NCT00264537
  • 11.6% vs 9.3% 4 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 8.6% vs 9.3% 2 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 44.6% vs 35.8% 100 mg + methotrexate · wk 24 · n 83 · Phase 3 · secondary NCT00264537
  • 44.2% vs 35.8% 50 mg + methotrexate · wk 24 · n 86 · Phase 3 · secondary NCT00264537
  • 25% vs 9.3% 4 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 18.6% vs 9.3% 2 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 44.4% vs 35.8% wk 24 · n 169 · Phase 3 · secondary NCT00264537
  • 34.8% vs 43.4% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896
ACR7026% vs 22.9%vs Adalimumabwk 24 · n 246NCT0197047516.1% vs 25.9%vs Golimumab100 mg · wk 24.14 · n 70NCT01715896
DAS28-CRP remission—Not reported—Trial running · NCT03414502
HAQ-DI, change—Not reported0.1 vs 0.1±0 vs placebo100 mg + placebo · wk 24 · n 133NCT00264550
8 other results
  • 0.5 vs 0.1 100 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.3 vs 0.1 100 mg + placebo · wk 14 · n 133 · Phase 3 · secondary NCT00264550
  • -0.3 vs 0.2 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 0.5 vs 0.1 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · secondary NCT00973479
  • 0.4 vs 0.1 100 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • -0.4 vs -0.6 100 mg · wk 24.14 · n 70 · Phase 2 · secondary NCT01715896
Modified Sharp score, change—Not reported1.3 vs 1.4−0.1 vs placebo100 mg + placebo · wk 52 · n 159NCT00264537
11 other results
  • 0.1 vs 1.4 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.7 vs 1.4 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.4 vs 1.4 wk 52 · n 318 · Phase 3 · primary NCT00264537
  • 2.2 vs 2.2 100 mg + placebo · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 0.2 vs 2.2 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 1.3 vs 2.2 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0.0 vs 1.1 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 0.7 vs 2.2 wk 52 · n 318 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 0 vs 0 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550

ACR20

adalimumab-atto (Amjevita)
74.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
golimumab
44.4% vs 33.1%+11.3 vs placebo100 mg + placebo · wk 14 · n 133NCT00264550
25 other results
  • 36.5% vs 18% 100 mg · wk 14 · n 148 · Phase 3 · primary NCT00299546
  • 40.9% vs 15.9% 50 mg · wk 14 · n 132 · Phase 3 · primary NCT01248780
  • 34.7% vs 18% 50 mg · wk 14 · n 147 · Phase 3 · primary NCT00299546
  • 58.5% vs 24.9% 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · primary NCT00973479
  • 56.2% vs 33.1% 100 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 55.1% vs 33.1% 50 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 51.6% vs 49.4% 100 mg + placebo · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 35.3% vs 27.8% 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 42.6% vs 16% 100 mg · wk 24 · n 148 · Phase 3 · secondary NCT00299546
  • 42.4% vs 15.9% 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 31.3% vs 16% 50 mg · wk 24 · n 147 · Phase 3 · secondary NCT00299546
  • 48.1% vs 27.9% 4 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 39.8% vs 27.9% 2 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 61.6% vs 49.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% wk 24 · n 318 · Phase 3 · secondary NCT00264537
  • 59.6% vs 27.8% 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 59.6% vs 27.8% 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 51.6% vs 27.9% 4 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 55% vs 27.9% 2 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 55.9% vs 37.1% 100 mg every 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 79.4% vs 37.1% 100 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 60% vs 37.1% 50 mg every 4 weeks · wk 16 · n 35 · Phase 2 · primary NCT00207714
  • 50% vs 37.1% 50 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 62% vs 65.6% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896

ACR50

adalimumab-atto (Amjevita)
49.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475
golimumab
32.7% vs 29.4%+3.3 vs placebo100 mg + placebo · wk 24 · n 159NCT00264537
19 other results
  • 19.4% vs 13.2% 4 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 12.5% vs 13.2% 2 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 36.5% vs 29.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 40.3% vs 29.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 21.1% vs 13.2% 4 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 21.7% vs 13.2% 2 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 38.4% vs 29.4% wk 24 · n 318 · Phase 3 · primary NCT00264537
  • 18.2% vs 6.7% 100 mg · wk 14 · n 148 · Phase 3 · secondary NCT00299546
  • 15% vs 6.7% 50 mg · wk 14 · n 147 · Phase 3 · secondary NCT00299546
  • 34.9% vs 13.2% 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 28.9% vs 35.8% 100 mg + placebo · wk 24 · n 90 · Phase 3 · secondary NCT00264537
  • 11.6% vs 9.3% 4 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 8.6% vs 9.3% 2 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 44.6% vs 35.8% 100 mg + methotrexate · wk 24 · n 83 · Phase 3 · secondary NCT00264537
  • 44.2% vs 35.8% 50 mg + methotrexate · wk 24 · n 86 · Phase 3 · secondary NCT00264537
  • 25% vs 9.3% 4 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 18.6% vs 9.3% 2 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 44.4% vs 35.8% wk 24 · n 169 · Phase 3 · secondary NCT00264537
  • 34.8% vs 43.4% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896

ACR70

adalimumab-atto (Amjevita)
26% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475
golimumab
16.1% vs 25.9%vs Golimumab100 mg · wk 24.14 · n 70NCT01715896

DAS28-CRP remission

adalimumab-atto (Amjevita)
—Not reported
golimumab
—Trial running · NCT03414502

HAQ-DI, change

adalimumab-atto (Amjevita)
—Not reported
golimumab
0.1 vs 0.1±0 vs placebo100 mg + placebo · wk 24 · n 133NCT00264550
8 other results
  • 0.5 vs 0.1 100 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.3 vs 0.1 100 mg + placebo · wk 14 · n 133 · Phase 3 · secondary NCT00264550
  • -0.3 vs 0.2 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 0.5 vs 0.1 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · secondary NCT00973479
  • 0.4 vs 0.1 100 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • -0.4 vs -0.6 100 mg · wk 24.14 · n 70 · Phase 2 · secondary NCT01715896

Modified Sharp score, change

adalimumab-atto (Amjevita)
—Not reported
golimumab
1.3 vs 1.4−0.1 vs placebo100 mg + placebo · wk 52 · n 159NCT00264537
11 other results
  • 0.1 vs 1.4 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.7 vs 1.4 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.4 vs 1.4 wk 52 · n 318 · Phase 3 · primary NCT00264537
  • 2.2 vs 2.2 100 mg + placebo · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 0.2 vs 2.2 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 1.3 vs 2.2 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0.0 vs 1.1 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 0.7 vs 2.2 wk 52 · n 318 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 0 vs 0 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. adalimumab-atto (Amjevita): 5 of 5 rows · golimumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-atto (Amjevita)golimumab
Rows use multiple source trials
DAS28-CRP
absolute change · score
-2.32 vs -2.32 Adalimumab score @ 24wka,b,c,d
NCT01970475 · Phase 3
-2.11 vs -2.4 Golimumab score @ 24.14wk100 mga,b,c,d
NCT01715896 · Phase 2 · registry result, not featured evidence
Dropout rate
8%e
NCT01970475 · Phase 3
36.5%100 mg + placeboe
NCT00264537 · Phase 3
show 35 more results
—100 mg SC
NCT00264537 · Phase 3
—50 mg SC
NCT00264537 · Phase 3
37.7%100 mg + methotrexate
NCT00264537 · Phase 3 · combination
31.4%50 mg + methotrexate
NCT00264537 · Phase 3 · combination
30.8%100 mg + placebo
NCT00264550 · Phase 3
—100 mg SC injections
NCT00264550 · Phase 3
—50 mg SC injections
NCT00264550 · Phase 3
33.7%100 mg + MTX
NCT00264550 · Phase 3 · combination
19.1%50 mg + MTX
NCT00264550 · Phase 3 · combination
—50mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—2mg/kg IV
NCT01004432 · Phase 3 · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
17.5%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
11.4%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
—100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
56.2%100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
60.1%50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
8.3%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
15.7%100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
23.5%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
14.7%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
20%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
29.4%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.7%e
NCT01970475 · Phase 3
20.1%100 mg + placeboe
NCT00264537 · Phase 3
show 35 more results
—100 mg SC
NCT00264537 · Phase 3
—50 mg SC
NCT00264537 · Phase 3
21.4%100 mg + methotrexate
NCT00264537 · Phase 3 · combination
15.1%50 mg + methotrexate
NCT00264537 · Phase 3 · combination
13.5%100 mg + placebo
NCT00264550 · Phase 3
—100 mg SC injections
NCT00264550 · Phase 3
—50 mg SC injections
NCT00264550 · Phase 3
15.7%100 mg + MTX
NCT00264550 · Phase 3 · combination
10.1%50 mg + MTX
NCT00264550 · Phase 3 · combination
—50mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—2mg/kg IV
NCT01004432 · Phase 3 · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
8.1%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
5.3%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
—100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
17.6%100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
14.4%50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
4.5%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
8.8%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
2.9%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
5.7%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
11.8%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Serious AEs
3.8%e
NCT01970475 · Phase 3
—100 mg + placeboe
NCT00264537 · Phase 3
show 35 more results
38.7%100 mg SC
NCT00264537 · Phase 3
32%50 mg SC
NCT00264537 · Phase 3
—100 mg + methotrexate
NCT00264537 · Phase 3 · combination
—50 mg + methotrexate
NCT00264537 · Phase 3 · combination
—100 mg + placebo
NCT00264550 · Phase 3
45.7%100 mg SC injections
NCT00264550 · Phase 3
31.4%50 mg SC injections
NCT00264550 · Phase 3
—100 mg + MTX
NCT00264550 · Phase 3 · combination
—50 mg + MTX
NCT00264550 · Phase 3 · combination
4.4%50mg SC
NCT01004432 · Phase 3 · combination
2.7%50 mg SC
NCT01004432 · Phase 3 · combination
4.6%50 mg SC
NCT01004432 · Phase 3 · combination
4.7%50 mg SC
NCT01004432 · Phase 3 · combination
5.4%2mg/kg IV
NCT01004432 · Phase 3 · combination
19.7%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
6.1%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
33.3%100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
—100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
34.7%50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
6%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
2.7%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
6.9%2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
6.8%50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
6.3%4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
13.3%2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
9.1%50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
14%4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
13.7%2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
2.9%100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
15.2%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
14.3%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
18.9%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
15.6%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
nasopharyngitis 6.4%
NCT01970475 · Phase 3
100 mg SCe
upper respiratory tract infection 25.5%
nausea 22.6%
bronchitis 16.5%
NCT00264537 · Phase 3
show 26 more results
50 mg SC
upper respiratory tract infection 26.2%
alanine aminotransferase increased 18%
bronchitis 15.1%
NCT00264537 · Phase 3
100 mg SC injections
upper respiratory tract infection 34.8%
cough 19%
nasopharyngitis 19%
NCT00264550 · Phase 3
50 mg SC injections
upper respiratory tract infection 37.1%
cough 22.9%
bronchitis 17.1%
NCT00264550 · Phase 3
50mg SC
rheumatoid arthritis 9.9%
arthralgia 8.8%
bronchitis 6.6%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 9.3%
depression 5.3%
sinusitis 5.3%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 6.7%
headache 5.5%
urinary tract infection 5.5%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
sinusitis 5.7%
NCT01004432 · Phase 3 · combination
2mg/kg IV
upper respiratory tract infection 8.2%
sinusitis 7.1%
bronchitis 6%
NCT01004432 · Phase 3 · combination
2 mg/kg + MTX
upper respiratory tract infection 13.7%
bronchitis 9.4%
rheumatoid arthritis 8.4%
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
50 mg
upper respiratory tract infection 19.1%
liver function test abnormal 6.1%
anaemia 1.5%
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
100 mg SC injections
upper respiratory tract infection 31.2%
nasopharyngitis 18.8%
rheumatoid arthritis 16.7%
NCT00299546 · Phase 3 · registry result, not featured evidence
50 mg SC injections
upper respiratory tract infection 25.5%
sinusitis 19.4%
headache 14.3%
NCT00299546 · Phase 3 · registry result, not featured evidence
50 mg subcutaneous
nasopharyngitis 0%
upper respiratory tract infection 0%
NCT00975130 · Phase 3 · registry result, not featured evidence
50 mg subcutaneous
nasopharyngitis 7.1%
upper respiratory tract infection 2.4%
NCT00975130 · Phase 3 · registry result, not featured evidence
2 mg/kg intravenous + 50 mg subcutaneous
upper respiratory tract infection 6.1%
nasopharyngitis 5.3%
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
50 mg
upper respiratory tract infection 8.5% (placebo 9.3%)
nasopharyngitis 7.7% (placebo 5.4%)
rheumatoid arthritis 5.1% (placebo 4.7%)
NCT00361335 · Phase 3 · registry result, not featured evidence
4 mg/kg
upper respiratory tract infection 12.6% (placebo 9.3%)
rheumatoid arthritis 9.4% (placebo 4.7%)
bronchitis 6.3% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence
2 mg/kg
rheumatoid arthritis 15.6% (placebo 4.7%)
upper respiratory tract infection 10.9% (placebo 9.3%)
bronchitis 7.8% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence
50 mg
upper respiratory tract infection 7.2% (placebo 9.3%)
rheumatoid arthritis 6.9% (placebo 4.7%)
bronchitis 5.3% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
4 mg/kg
upper respiratory tract infection 12.2% (placebo 9.3%)
nausea 10.7% (placebo 7%)
bronchitis 7.7% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
2 mg/kg
upper respiratory tract infection 12.1% (placebo 9.3%)
nausea 11% (placebo 7%)
headache 9.3% (placebo 10.1%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
100 mg
nasopharyngitis 5.7%
headache 4.3%
hepatic enzyme increased 4.3%
NCT01715896 · Phase 2 · registry result, not featured evidence
100 mg every 4 weeks
headache 27.3% (placebo 20.6%)
nausea 21.2% (placebo 5.9%)
upper respiratory tract infection 15.2% (placebo 20.6%)
NCT00207714 · Phase 2 · registry result, not featured evidence
100 mg every 2 or 4 weeks
injection site erythema 28.6% (placebo 11.8%)
nasopharyngitis 22.9% (placebo 8.8%)
nausea 22.9% (placebo 5.9%)
NCT00207714 · Phase 2 · registry result, not featured evidence
50 mg every 4 weeks
headache 21.6% (placebo 20.6%)
nasopharyngitis 21.6% (placebo 8.8%)
rheumatoid arthritis 21.6% (placebo 14.7%)
NCT00207714 · Phase 2 · registry result, not featured evidence
50 mg every 2 or 4 weeks
nausea 25% (placebo 5.9%)
rheumatoid arthritis 21.9% (placebo 14.7%)
headache 18.8% (placebo 20.6%)
NCT00207714 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 24.14 weeks versus 24 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

golimumab

Modified Sharp 1.25 vs 1.37 placebo score @ 52wk100 mg + placebo
absolute change · score
NCT00264537 · Phase 3
show 11 more results
2.19 vs 2.16 placebo score @ 52wk100 mg + placebo
NCT00264537 · Phase 3
0 vs 0 placebo score @ 24wk100 mg + placebo
NCT00264550 · Phase 3
0.07 vs 1.37 placebo score @ 52wk100 mg + methotrexate
NCT00264537 · Phase 3 · combination
0.16 vs 2.16 placebo score @ 52wk100 mg + methotrexate
NCT00264537 · Phase 3 · combination
0 vs 0 placebo score @ 24wk100 mg + MTX
NCT00264550 · Phase 3 · combination
0.74 vs 1.37 placebo score @ 52wk50 mg + methotrexate
NCT00264537 · Phase 3 · combination
1.29 vs 2.16 placebo score @ 52wk50 mg + methotrexate
NCT00264537 · Phase 3 · combination
0 vs 0 placebo score @ 24wk50 mg + MTX
NCT00264550 · Phase 3 · combination
0.03 vs 1.09 placebo score @ 24wk2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
0.41 vs 1.37 placebo score @ 52wk
NCT00264537 · Phase 3 · combination
0.74 vs 2.16 placebo score @ 52wk
NCT00264537 · Phase 3 · combination
EULAR 63.2% (n=133) vs 50.4% (n=133) placebo @ 14wk100 mg + placebo
responder rate · % of participants
NCT00264550 · Phase 3 · converted to % from 84 Participants as posted
show 4 more results
58.8% (n=148) vs 29.3% (n=150) placebo @ 14wk*100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
55.8% (n=147) vs 29.3% (n=150) placebo @ 14wk*50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence · converted to % from 82 participants as posted
75.3% (n=89) vs 50.4% (n=133) placebo @ 14wk*100 mg + MTX
NCT00264550 · Phase 3 · combination · converted to % from 67 Participants as posted
71.9% (n=89) vs 50.4% (n=133) placebo @ 14wk*50 mg + MTX
NCT00264550 · Phase 3 · combination · converted to % from 64 Participants as posted
HAQ-DI 0.125 vs 0.125 placebo score @ 24wk100 mg + placebo
absolute change · score
NCT00264550 · Phase 3
show 8 more results
0.25 vs 0.125 placebo score @ 14wk100 mg + placebo
NCT00264550 · Phase 3
-0.4 vs -0.59 Golimumab score @ 24.14wk100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
-0.2623 vs 0.1525 placebo score @ 24wk50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
0.5 vs 0.125 placebo score @ 24wk100 mg + MTX
NCT00264550 · Phase 3 · combination
0.375 vs 0.125 placebo score @ 14wk100 mg + MTX
NCT00264550 · Phase 3 · combination
0.375 vs 0.125 placebo score @ 24wk50 mg + MTX
NCT00264550 · Phase 3 · combination
0.375 vs 0.125 placebo score @ 14wk50 mg + MTX
NCT00264550 · Phase 3 · combination
0.5 vs 0.125 placebo score @ 14wk2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
ACR20 34.9% (n=433) @ 14wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
NCT01004432 · Phase 3 · combination
show 3 more results
24.5% (n=433) @ 2wk50 mg SC
NCT01004432 · Phase 3 · combination
13.2% (n=91) @ 52wk50 mg SC
NCT01004432 · Phase 3 · combination
9.2% (n=184) @ 52wk2 mg/kg IV
NCT01004432 · Phase 3 · combination
EULAR 22.7% (n=75) @ 52wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
NCT01004432 · Phase 3 · combination
show 6 more results
64.8% (n=3280) @ 8.67wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2127 Participants as posted
76.9% (n=3280) @ 17.33wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2522 Participants as posted
82.1% (n=3280) @ 26wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2692 Participants as posted
67% (n=3280) @ 8.67wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2199 Participants as posted
77.1% (n=3280) @ 17.33wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2530 Participants as posted
81.3% (n=3280) @ 26wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2667 Participants as posted
ACR20 7.9% (n=63) @ 76wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
show 3 more results
8.5% (n=47) @ 76wk50 mg SC
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
11.8% (n=212) @ 76wk50 mg SC
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
15.7% (n=102) @ 76wk2 mg/kg IV
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
DAS28-ESR -0.136 score @ 76wk50 mg SC
absolute change · score
No placebo or comparator arm
NCT01004432 · Phase 3 · combination
show 3 more results
0.209 score @ 76wk50 mg SC
NCT01004432 · Phase 3 · combination
-0.013 score @ 76wk50 mg SC
NCT01004432 · Phase 3 · combination
-0.017 score @ 76wk2 mg/kg IV
NCT01004432 · Phase 3 · combination
EULAR Good, Moderate 64.3% (n=129) vs 44.2% (n=129) placebo @ 14wk4 mg/kg
responder rate · % of participants
NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
show 4 more results
62.5% (n=128) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
73.4% (n=128) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 94 Participants as posted
81.3% (n=395) vs 40.1% (n=197) placebo @ 14wk2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
69% (n=129) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 89 Participants as posted
HAQ-DI 0.25 vs 0 placebo score @ 24wk100 mg
absolute value · score
NCT00299546 · Phase 3 · registry result, not featured evidence
show 1 more result
0.125 vs 0 placebo score @ 24wk50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
EULAR Good, Moderate 82.1% (n=3280) @ 24wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2692 Participants as posted
DAS28-ESR Remission 25.8% (n=248) @ 43.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Start of Month 11
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
show 1 more result
24% (n=242) @ 43.3wk*2 mg/kg intravenous + 50 mg subcutaneous
Start of Month 11
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 58 Participants as posted
DAS28-ESR Remission 27% (n=248) @ 52wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
End of Month 12
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
show 1 more result
24.4% (n=242) @ 52wk*2 mg/kg intravenous + 50 mg subcutaneous
End of Month 12
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 59 Participants as posted

+ 34 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · golimumab's landscape